UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Journal of clinical oncology, 2023-02, Vol.41 (6), p.1285-1295

2023

Volltextzugriff (PDF)

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3697-3705

2005

Volltextzugriff (PDF)

The Unworthy Scholar from Pingjiang: Republican-Era Martial Arts Fiction

Hamm, John Christopher

1, 2019

Volltextzugriff (PDF)

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2007-05, Vol.25 (15), p.1960-1966

2007

Volltextzugriff (PDF)

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

The lancet oncology, 2013-11, Vol.14 (12), p.1216-1225

2013

Volltextzugriff (PDF)

The Road to Reintegration: Status and Continuing Support of the U.S. Air Force's Wounded, Ill, and Injured

Rand health quarterly, 2024-03, Vol.11 (2), p.3-3

2024

Volltextzugriff (PDF)

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast cancer research and treatment, 2022-06, Vol.193 (3), p.555-564

2022

Volltextzugriff (PDF)

The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer

Physical therapy, 2020-03, Vol.100 (3), p.416-428

2020

Volltextzugriff (PDF)

Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3153-3159

2017

Volltextzugriff (PDF)

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast cancer research and treatment, 2022-06, Vol.193 (3), p.565-565

2022

Volltextzugriff (PDF)

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.153-161

2022

Volltextzugriff (PDF)

Multidisciplinary approach to low-dose CT screening for lung cancer in a metropolitan community

Family practice, 2020-02, Vol.37 (1), p.25-29

2020

Volltextzugriff (PDF)

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

Clinical cancer research, 2013-01, Vol.19 (1), p.268-278

2013

Volltextzugriff (PDF)

Molecular targeting in cancer therapy: can we fulfill the promise?

Oncology (Williston Park, N.Y.), 2012-11, Vol.26 (11), p.1040, 1042-1042

Hamm, John T

2012

Volltextzugriff (PDF)

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

Cancer, 2013-07, Vol.119 (14), p.2555-2563

2013

Volltextzugriff (PDF)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e007047

2023

Volltextzugriff (PDF)

Toward Resiliency in the Joint Blood Supply Chain

Rand health quarterly, 2019-05, Vol.8 (3), p.9-9

2019

Volltextzugriff (PDF)

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A844-A844

2023

Volltextzugriff (PDF)

735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A828-A828

2023

Volltextzugriff (PDF)

599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A682-A682

2023

Volltextzugriff (PDF)

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A836-A837

2023

Volltextzugriff (PDF)

Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2009-12, Vol.15 (24), p.7719-7725

2009

Volltextzugriff (PDF)

Mastery of Words and Swords: Negotiating Intellectual Masculinities in Modern China, 1890s-1930s by Jun Lei (review)

China review international, 2020, Vol.27 (3&4), p.212-217

Hamm, John

2020

Volltextzugriff (PDF)

Strengthening vaccination assessment at a southern oncology center: A quality improvement endeavor

JCO oncology practice, 2024-10, Vol.20 (10_suppl), p.322-322

2024

Volltextzugriff (PDF)

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2011-12, Vol.74 (3), p.474-480

2011

Volltextzugriff (PDF)

1 – 25 von 696

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(519)
Mit Volltextzugriff
(580)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(666)
Deutsch
(26)
Spanisch
(4)
Japanisch
(2)
Polnisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

The Unworthy Scholar from Pingjiang: Republican-Era Martial Arts Fiction

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

The Road to Reintegration: Status and Continuing Support of the U.S. Air Force's Wounded, Ill, and Injured

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer

Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

Multidisciplinary approach to low-dose CT screening for lung cancer in a metropolitan community

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

Molecular targeting in cancer therapy: can we fulfill the promise?

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Toward Resiliency in the Joint Blood Supply Chain

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer

599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck

Mastery of Words and Swords: Negotiating Intellectual Masculinities in Modern China, 1890s-1930s by Jun Lei (review)

Strengthening vaccination assessment at a southern oncology center: A quality improvement endeavor

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

Suchergebnisse filtern